![]() | |
Clinical data | |
---|---|
Other names | Volitinib |
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.238.920 |
Chemical and physical data | |
Formula | C17H15N9 |
Molar mass | 345.370 g·mol−1 |
3D model (JSmol) | |
| |
|
Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2] It has been given conditional approval for these indication in China.[3]
References
- ^ "Savolitinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. American Medical Association. 26 October 2016.
- ^ "Savolitinib - AstraZeneca/Hutchison China MediTech Limited". AdisInsight. Springer Nature Switzerland AG.
- ^ Markham A (September 2021). "Savolitinib: First Approval". Drugs. 81 (14): 1665–1670. doi:10.1007/s40265-021-01584-0. PMID 34455538. S2CID 237344020.
External links
- "Savolitinib". Drug Information Portal. U.S. National Library of Medicine.